Dr. Yong-Zu Kim, CEO of LegoChem Biosciences gave a presentation at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an American Society for Microbiology (ASM) meeting. 

Title: Recent Progress of Discovering New Oxazolidinones

Date: Sep 2011

Summary: 

Several newly developed cyclic amidrazone or amidoxime derivatives of oxazolidinone display activity against linezolid-resistant gram-positive pathogens. With linezolid still the only oxazolidinone approved for human use, LegoChem Biosciences is continuing to optimize our lead compound and to support further development for use against gram-positive pathogens.

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).